Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 9
Submit an article Journal homepage
264
Views
8
CrossRef citations to date
0
Altmetric
Theme: Heart Failure - Review

A review of current therapies used in the treatment of congestive heart failure

Raj Parikh Department of Internal Medicine, Rush University Medical Center 1653 W Congress Pkwy Chicago, IL 60612, USA; Department of Internal Medicine, Rush University Medical Center 1653 W Congress Pkwy Chicago, IL 60612, USACorrespondence[email protected] [email protected]
&
Philip J Kadowitz Department of Pharmacology, Tulane University School of Medicine 1430 Tulane Avenue, SL83 New Orleans, LA 70112, USA; Department of Pharmacology, Tulane University School of Medicine 1430 Tulane Avenue, SL83 New Orleans, LA 70112, USACorrespondence[email protected] [email protected]
Pages 1171-1178 | Published online: 10 Jan 2014

References

  • Hunt SA, Abraham WT, Chin MH et al.; Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults, a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53(15), e1–e90 (2009).
  • Hunt SA; ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 46(6), e1–82 (2005).
  • Roger VL, Go AS, Lloyd-Jones DM et al.; Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation 123(4), e18–e209 (2011).
  • Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 360(14), 1418–1428 (2009).
  • Lloyd-Jones D, Adams RJ, Brown TM et al.; Executive summary, heart disease and stroke statistics–2010 update, a report from the American Heart Association. Circulation 121(7), 948–954 (2010).
  • The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429–1435 (1987).
  • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325(5), 293–302 (1991).
  • The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327(10), 685–691 (1992).
  • Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349(9054), 747–752 (1997).
  • Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure, randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet 355(9215), 1582–1587 (2000).
  • Konstam MA, Neaton JD, Dickstein K et al.; Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study), a randomised, double-blind trial. Lancet 374(9704), 1840–1848 (2009).
  • Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN; Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 40(8), 1414–1421 (2002).
  • McMurray JJ, Ostergren J, Swedberg K et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors, the CHARM-Added trial. Lancet 362(9386), 767–771 (2003).
  • Granger CB, McMurray JJ, Yusuf S et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors, the CHARM-Alternative trial. Lancet 362(9386), 772–776 (2003).
  • Yusuf S, Pfeffer MA, Swedberg K et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction, the CHARM-Preserved Trial. Lancet 362(9386), 777–781 (2003).
  • Carson P, Massie BM, McKelvie R et al.; I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial, rationale and design. J. Card. Fail. 11(8), 576–585 (2005).
  • Loeb HS, Johnson G, Henrick A et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87(6 Suppl), VI78–VI87 (1993).
  • Franciosa JA, Taylor AL, Cohn JN et al.; A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT), rationale, design, and methodology. J. Card. Fail. 8(3), 128–135 (2002).
  • Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction, the CAPRICORN randomised trial. Lancet 357(9266), 1385–1390 (2001).
  • Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334(21), 1349–1355 (1996).
  • Packer M, Coats AJ, Fowler MB et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344(22), 1651–1658 (2001).
  • CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 9(4), 1765–1773 (1994).
  • CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised trial. Lancet 353(9146), 9–13 (1999).
  • MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169), 2001–2007 (1999).
  • Poole-Wilson PA, Swedberg K, Cleland JG et al.; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET), randomised controlled trial. Lancet 362(9377), 7–13 (2003).
  • Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709–717 (1999).
  • Pitt B, Williams G, Remme W et al. The EPHESUS trial, eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. 15(1), 79–87 (2001).
  • Zannad F, McMurray JJ, Krum H et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364(1), 11–21 (2011).
  • The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336, 525–533 (1997).
  • Murray MD, Deer MM, Ferguson JA et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med. 111(7), 513–520 (2001).
  • Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325(21), 1468–1475 (1991).
  • Cuffe MS, Califf RM, Adams KF et al. Rationale and design of the OPTIME CHF trial, outcomes of a prospective trial, of intravenous milrinone for exacerbations of chronic heart failure. Am. Heart J. 9, 15–22 (2000).
  • Burger AJ, Horton DP, LeJemtel T et al.; Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure, the PRECEDENT study. Am. Heart J. 144(6), 1102–1108 (2002).
  • Mebazaa A, Nieminen MS, Packer M et al.; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure, the SURVIVE Randomized Trial. JAMA 297(17), 1883–1891 (2007).
  • Packer M. REVIVE II. Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Presented at: American Heart Association Scientific Sessions. Dallas, TX, USA, 14 November 2005.
  • Metra M, Eichhorn E, Abraham WT et al.; ESSENTIAL Investigators. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure, the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur. Heart J. 30(24), 3015–3026 (2009).
  • Zewail AM, Nawar M, Vrtovec B, Eastwood C, Kar MN, Delgado RM 3rd. Intravenous milrinone in treatment of advanced congestive heart failure. Tex. Heart Inst. J. 30(2), 109–113 (2003).
  • Patel MB, Kaplan IV, Patni RN et al. Sustained Improvement in flow-mediated vasodilation after short-term administration of dobutamine in patients with severe congestive heart failure. Circulation 99(1), 60–64 (1999).
  • Katz SD, Yuen J, Bijou R, LeJemtel TH. Training improves endothelium-dependent vasodilation in resistance vessels of patients with heart failure. J. Appl. Physiol. 82(5), 1488–1492 (1997).
  • Moss AJ, Zareba W, Hall WJ et al.; Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346(12), 877–883 (2002).
  • Bardy GH, Lee KL, Mark DB et al.; Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N. Engl. J. Med. 352(3), 225–237 (2005).
  • Kadish A, Dyer A, Daubert JP et al.; Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med. 350(21), 2151–2158 (2004).
  • Young JB, Abraham WT, Smith AL et al.; Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. Multicenter In-Sync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. JAMA 289(20), 2685–2694 (2003).
  • Cleland JG, Daubert JC, Erdmann E et al.; The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539–1549 (2005).
  • Moss AJ, Hall WJ, Cannom DS et al.; Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361(14), 1329–1338 (2009).
  • Granger BB, Ekman I, Granger CB et al. Adherence to medication according to sex and age in the CHARM programme. Eur. J. Heart Fail. 11(11), 1092–1098 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.